Results 261 to 270 of about 212,526 (280)

Targeting non-malignant disorders with tyrosine kinase inhibitors

Nature Reviews Drug Discovery, 2010
Friedrich Grimminger, Ralph T Schermuly
exaly  

Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

Lancet, The, 2007
Risto Kerkelä, Jayesh Desai, Suzanne George   +2 more
exaly  

Lung cancer: New biological insights and recent therapeutic advances

Ca-A Cancer Journal for Clinicians, 2011
Taofeek Kunle Owonikoko, Fadlo R Khuri, Suresh S Ramalingam   +2 more
exaly  

Relation between resistance of Philadelphia-chromosome-positive acute lymphoblastic leukaemia to the tyrosine kinase inhibitor STI571 and gene-expression profiles: a gene-expression study

Lancet, The, 2002
David Elashoff, Dieter Hoelzer, H Phillip Koeffler   +2 more
exaly  

Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC

Nature Reviews Clinical Oncology, 2009
Helena Linardou, Samuel Murray
exaly  

Hypothyroidism related to tyrosine kinase inhibitors: an emerging toxic effect of targeted therapy

Nature Reviews Clinical Oncology, 2009
Francesco Torino, Agnese Barnabei, Giampietro Gasparini   +2 more
exaly  

Kinase inhibitors: the road ahead

Nature Reviews Drug Discovery, 2018
Fleur M Ferguson, Nathanael S Gray
exaly  

Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia

New England Journal of Medicine, 2001
Brian J Druker, Moshe Talpaz, Hagop M Kantarjian   +2 more
exaly  

Bruton's tyrosine kinase (BTK) as a promising target in solid tumors.

Cancer Treatment Reviews, 2017
J. Molina-Cerrillo, T. Alonso-Gordoa, P. Gajate, Enrique Grande   +3 more
semanticscholar   +1 more source

The SYK tyrosine kinase: a crucial player in diverse biological functions

Nature Reviews Immunology, 2010
Attila Mócsai, Jürgen Ruland, Victor L J Tybulewicz   +2 more
exaly